NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Cytokinetics, Incorporated CYTK
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$88.0M
▲ 376.6% vs FY2024
EPS · FY25
$-6.54
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-891.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 88.0M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 892 cents on every revenue dollar this year.
Per share
USD -6.54
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-695.4%
Net margin-891.6%
Return on assets-55.5%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+9.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.4%
+9.5%
+11.9%
+26.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.12B
Shares outstanding, FY2025
Change, 5 years+73.1%
Change, 10 years+210.6%
The share count grew 73% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.4B
total assets, end of FY2025
Total assetsUSD 1.4B
EquityUSD -659.6M
CashUSD 122.5M
Gross debtUSD 287.6M
Net debtUSD 165.0M
Current ratio4.53×
Net debt stands at -25% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.1
0.0
0.0
0.1
0.1
0.1
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.1
·
·
Operating income $B
−0.6
−0.5
−0.5
−0.3
−0.2
−0.1
−0.1
−0.1
−0.1
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
·
·
EBITDA $B
−0.6
−0.5
−0.5
−0.3
−0.2
−0.1
−0.1
−0.1
−0.1
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
·
·
Net income $B
−0.8
−0.6
−0.5
−0.4
−0.2
−0.1
−0.1
−0.1
−0.1
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.1
−0.0
EPS, diluted $
−6.54
−5.26
−5.45
−4.33
−2.80
−1.97
−2.11
−1.95
−2.59
0.39
−0.97
−0.41
−1.24
−2.30
−4.30
−0.77
0.42
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
−572.1
−120.5
−248.5
−1622.9
−156.6
−125.2
20.2
−46.7
−20.0
−54.2
−68.3
−80.6
−57.3
32.5
−75.3
−48.9
Shares out B
0.12
0.12
0.10
0.09
0.08
0.07
0.06
0.05
0.05
0.04
0.04
0.04
0.03
0.02
0.07
0.07
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed